Compare EFC & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFC | PGEN |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | 500 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2013 |
| Metric | EFC | PGEN |
|---|---|---|
| Price | $12.70 | $4.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $14.55 | $8.33 |
| AVG Volume (30 Days) | 1.5M | ★ 5.4M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 12.32% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | $43.05 | $81.04 |
| P/E Ratio | $9.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.28 | $1.23 |
| 52 Week High | $14.12 | $5.47 |
| Indicator | EFC | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 53.07 |
| Support Level | $12.37 | $3.31 |
| Resistance Level | $14.00 | $4.44 |
| Average True Range (ATR) | 0.22 | 0.34 |
| MACD | 0.14 | 0.07 |
| Stochastic Oscillator | 94.72 | 71.43 |
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. It acquires reverse mortgage loans both through its origination activities and through secondary market purchases.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.